ResistancePlus® MG (CE-IVD)
simultaneously detects Mycoplasma genitalium and 5 mutations at positions 2058 and 2059 in the 23S rRNA gene (E. coli numbering) that are associated with resistance to azithromycin (macrolide-based antibiotic). ResistancePlus® MG based on the Class-leading PlexPCR® technology utilising two proprietary technologies: PlexZyme® and PlexPrime®. This technology enables high performance and reliable multiplex qPCR compared to other probe-based methods.
| Targets | Single Well, M. genitalium (MgPa), A2058G, A2059G, A2059C, A2058T, A2058C, Internal control |
| Validated Sample Types | Urine, swabs (anal, rectal, cervical, endocervical, vaginal and urethral), pre-extracted samples |
| Storage & Stability | Expiry dates are stated on the labels. It is recommended that freeze/thaw cycles be limited to less than 15. Store protected from light at – 20°C. |
| Validated RT-PCR Systems | LightCycler® 480 Instrument II (LC480 II, Roche), Applied Biosystems® 7500 Fast (7500 Fast), Applied Biosystems® 7500 Fast Dx (7500 Fast Dx), Bio-Rad CFX96™ IVD (CFX96 IVD), Bio-Rad CFX96™ CFX96 Touch™ (CFX96 Touch) |
| Package Size | 25 reactions/box |
Sexually Transmitted Infections
Why Use ?
Resistance to the macrolide treatment (Azithromycin) is of growing concern when managing M. genitalium (Mgen) infections. Guidelines around the world now call for the practice of Resistance Guided Therapy to guide appropriate treatment decisions, reduce potential for spreading infection among vulnerable populations, and support antibiotic stewardship.
• Resistance Guided Therapy is clinically demonstrated to improve patient cure rate and overall patient management.
• Detection of macrolide resistance can reduce time to cure, preventing ongoing transmission.
Tested on thousands of clinical samples, demonstrates excellent sensitivity and specificity.